$0.869200
0.044.85%
Pre-Market: Jul 19, 6:07 PM EDT
15 minutes delayed
Comments
Loading...
TransCode Therapeutics
RNAZNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
TransCode Therapeutics (NASDAQ:RNAZ) Stock, Analyst Ratings, Price Targets, Forecasts
TransCode Therapeutics Inc has a consensus price target of $3 based on the ratings of 1 analysts. The high is $3 issued by HC Wainwright & Co. on May 29, 2024. The low is $3 issued by HC Wainwright & Co. on May 29, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 29, 2024, May 16, 2024, and April 16, 2024, respectively. With an average price target of $3 between HC Wainwright & Co., there's an implied 245.14% upside for TransCode Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for TransCode Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/29/2024 | Buy Now | 245.14% | HC Wainwright & Co. | Emily Bodnar | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 245.14% | HC Wainwright & Co. | Emily Bodnar | → $3 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | 245.14% | HC Wainwright & Co. | Emily Bodnar | → $3 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 245.14% | HC Wainwright & Co. | Emily Bodnar | → $3 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | Buy Now | 245.14% | HC Wainwright & Co. | Emily Bodnar | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 1280.58% | HC Wainwright & Co. | Emily Bodnar | → $480 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2022 | Buy Now | 590.29% | HC Wainwright & Co. | Emily Bodnar | $8000 → $4800 | Maintains | Buy | Get Alert |
| 06/07/2022 | Buy Now | 1050.48% | HC Wainwright & Co. | Emily Bodnar | → $8000 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for TransCode Therapeutics (RNAZ) stock?
The latest price target for TransCode Therapeutics (NASDAQ:RNAZ) was reported by HC Wainwright & Co. on May 29, 2024. The analyst firm set a price target for $3.00 expecting RNAZ to rise to within 12 months (a possible 245.14% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TransCode Therapeutics (RNAZ)?
The latest analyst rating for TransCode Therapeutics (NASDAQ:RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics reiterated their buy rating.
When was the last upgrade for TransCode Therapeutics (RNAZ)?
There is no last upgrade for TransCode Therapeutics
When was the last downgrade for TransCode Therapeutics (RNAZ)?
There is no last downgrade for TransCode Therapeutics.
When is the next analyst rating going to be posted or updated for TransCode Therapeutics (RNAZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on May 29, 2024 so you should expect the next rating to be made available sometime around May 29, 2025.
Is the Analyst Rating TransCode Therapeutics (RNAZ) correct?
While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a reiterated with a price target of $3.00 to $3.00. The current price TransCode Therapeutics (RNAZ) is trading at is $0.87, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.